Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted hea...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2017-01-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/20016689.2017.1345580 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849305901237796864 |
|---|---|
| author | Zoltán Kaló Zoltán Vokó Andrew Östör Emma Clifton-Brown Radu Vasilescu Alysia Battersby Edward Gibson |
| author_facet | Zoltán Kaló Zoltán Vokó Andrew Östör Emma Clifton-Brown Radu Vasilescu Alysia Battersby Edward Gibson |
| author_sort | Zoltán Kaló |
| collection | DOAJ |
| description | Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted healthcare budgets. This study compares the size of RA patient populations with access to reimbursed bDMARDs across 37 European countries, Russia, and Turkey, according to their treatment eligibility defined by European League Against Rheumatism (EULAR) recommendations and national reimbursement criteria. Methods: The size of the RA patient population eligible for bDMARD treatment was estimated in a population model using published RA epidemiological data and clinical criteria defined by 2013 EULAR recommendations along with national reimbursement criteria defined in a survey of the 39 countries in November 2015. Results: According to EULAR recommendations, 32% of the total RA population in the European region is eligible for bDMARD treatment. However, only an average 59% of this EULAR-eligible population remains eligible after applying national reimbursement criteria (from 86% in ‘high access’ to 13% in ‘low-access’ countries). Conclusion: Access to reimbursed bDMARDs remains unequal in the European region. As biosimilars of bDMARDs are introduced, changes in reimbursement criteria may increase access to bDMARDs and reduce this inequality. |
| format | Article |
| id | doaj-art-3543e6bba6874e06808d97ba0b2ff0b3 |
| institution | Kabale University |
| issn | 2001-6689 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Market Access & Health Policy |
| spelling | doaj-art-3543e6bba6874e06808d97ba0b2ff0b32025-08-20T03:55:16ZengMDPI AGJournal of Market Access & Health Policy2001-66892017-01-015110.1080/20016689.2017.13455801345580Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European regionZoltán Kaló0Zoltán Vokó1Andrew Östör2Emma Clifton-Brown3Radu Vasilescu4Alysia Battersby5Edward Gibson6Eötvös Loránd UniversityEötvös Loránd UniversityRheumatology Clinical Research Unit, Addenbrookes HospitalGlobal Health & Value, Pfizer LtdGlobal Health & Value, Pfizer LtdWickenstonesWickenstonesBackground & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted healthcare budgets. This study compares the size of RA patient populations with access to reimbursed bDMARDs across 37 European countries, Russia, and Turkey, according to their treatment eligibility defined by European League Against Rheumatism (EULAR) recommendations and national reimbursement criteria. Methods: The size of the RA patient population eligible for bDMARD treatment was estimated in a population model using published RA epidemiological data and clinical criteria defined by 2013 EULAR recommendations along with national reimbursement criteria defined in a survey of the 39 countries in November 2015. Results: According to EULAR recommendations, 32% of the total RA population in the European region is eligible for bDMARD treatment. However, only an average 59% of this EULAR-eligible population remains eligible after applying national reimbursement criteria (from 86% in ‘high access’ to 13% in ‘low-access’ countries). Conclusion: Access to reimbursed bDMARDs remains unequal in the European region. As biosimilars of bDMARDs are introduced, changes in reimbursement criteria may increase access to bDMARDs and reduce this inequality.http://dx.doi.org/10.1080/20016689.2017.1345580Biological disease-modifying antirheumatic drugs (bDMARDs)rheumatoid arthritisreimbursementbiosimilars |
| spellingShingle | Zoltán Kaló Zoltán Vokó Andrew Östör Emma Clifton-Brown Radu Vasilescu Alysia Battersby Edward Gibson Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region Journal of Market Access & Health Policy Biological disease-modifying antirheumatic drugs (bDMARDs) rheumatoid arthritis reimbursement biosimilars |
| title | Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region |
| title_full | Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region |
| title_fullStr | Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region |
| title_full_unstemmed | Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region |
| title_short | Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region |
| title_sort | patient access to reimbursed biological disease modifying antirheumatic drugs in the european region |
| topic | Biological disease-modifying antirheumatic drugs (bDMARDs) rheumatoid arthritis reimbursement biosimilars |
| url | http://dx.doi.org/10.1080/20016689.2017.1345580 |
| work_keys_str_mv | AT zoltankalo patientaccesstoreimbursedbiologicaldiseasemodifyingantirheumaticdrugsintheeuropeanregion AT zoltanvoko patientaccesstoreimbursedbiologicaldiseasemodifyingantirheumaticdrugsintheeuropeanregion AT andrewostor patientaccesstoreimbursedbiologicaldiseasemodifyingantirheumaticdrugsintheeuropeanregion AT emmacliftonbrown patientaccesstoreimbursedbiologicaldiseasemodifyingantirheumaticdrugsintheeuropeanregion AT raduvasilescu patientaccesstoreimbursedbiologicaldiseasemodifyingantirheumaticdrugsintheeuropeanregion AT alysiabattersby patientaccesstoreimbursedbiologicaldiseasemodifyingantirheumaticdrugsintheeuropeanregion AT edwardgibson patientaccesstoreimbursedbiologicaldiseasemodifyingantirheumaticdrugsintheeuropeanregion |